Study wrapper · #1318
Intranasal delivery of Semaglutide using a thermoresponsive PNPHO nanocarrier: formulation development, characterization and biological evaluation.
Editor's note
This is early formulation science - physicochemical characterisation, cell-layer permeation and rodent pharmacodynamics - not a clinical study, and the efficacy comparisons are against free drug in the same experimental systems. A needle-free nasal route is a genuinely interesting direction given how much of this market runs on weekly injections, but the gap between a rodent glucose-tolerance curve and a human bioavailability figure is large. Several authors list affiliations that suggest industry involvement in the delivery platform; no funding statement is visible in the abstract.
Plain-language abstract
Researchers built a temperature-responsive polymer nanoparticle carrying semaglutide and tested whether it could be absorbed through the nose instead of injected. The particles averaged about 26 nm, held 89 percent of the drug, resisted enzyme breakdown and crossed nasal cells better than semaglutide alone in laboratory tests. In animals, the formulation stayed in the sinus region longer and improved glucose tolerance over a 24-hour dosing window, with no detectable drug signal reaching the brain.